Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very early PET-adapted ABVD versus escalated BEACOPP in advanced Hodgkin lymphoma
NL-OMON39829Phase 3Not yet recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide and 4 more in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Freedom from treatment failure. Planned start Feb 2014; status: not yet recruiting.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON39829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39829.